Inflammation and antiangiogenesis in cancer

Current Medicinal Chemistry

Volumn 19, Issue 7, 2012, Pages 955-960

  Ribatti, D ^a   Crivellato, E ^b   Vacca, A ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Adaptive immunity; Angiogenesis; Anti angiogenesis; Inflammation; Innate immunity; Lymphocytes; Macrophages; Mast cells; Neutrophils; Platelets; Tumor progression

Indexed keywords

ACETYLSALICYLIC ACID; ATIPRIMOD; COLONY STIMULATING FACTOR 1; COMPACTIN; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR 2; GABEXATE MESILATE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 8; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; NAFAMSTAT MESILATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; RANTES; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; ZOLEDRONIC ACID;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; B LYMPHOCYTE; BLADDER CANCER; BREAST CANCER; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; GRANULOCYTE; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; LUNG CANCER; MACROPHAGE; MAST CELL; MONOCYTE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; REVIEW; T LYMPHOCYTE; THROMBOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84858224962     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799320655     Document Type: Review

References (115)

1. Gregory, A.D.; Houghton, A.M. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res., 2011, 71, 2411-2416
2. Ribatti, D.; Vacca, A. Overview of angiogenesis during tumor growth. In: An integrative approach from science to medicine; Figg & Folkman, Ed.; Angiogenesis. V: New York: Springer; 2008; pp. 161-168
3. Queen, M.M.; Ryan, R.E.; Holzer, R.G.; Keller-Peck, C.R.; Jorcyk, C.L. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res., 2005, 65, 8896-8904 (Pubitemid 41377379)
4. Coussens, L.M.; Werb, Z. Matrix metalloproteinases and the development of cancer. Chem. Biol., 1996, 3, 895-904 (Pubitemid 27017088)
5. Nozawa, H.; Chiu, C.; Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 12493-12498 (Pubitemid 44267286)
6. Masson, V.; De La Ballina, L.R.; Munaut, C.; Wielockx, B,; Jost, M.; Mailard, C.; Blacher, S.; Bajou, K.; Itoh, T.; Itohara, S.; Werb, Z.; Libert, C.; Foidart, J.M.; Noël, A. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J., 2005, 19, 234-236
7. Obermueller, E.; Vosseler, S.; Fusenig, N.E.; Mueller, M.M. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res., 2004, 64, 7801-7812 (Pubitemid 39446913)
8. Gutschalk, C.M.; Herold-Mende, C.C.; Fusenig, N.E.; Mueller, M.M. Granulocyte colony-stimulating factor and granulocyte-macrophage colonystimulating factor promote malignant growth of cells from head and neck squamous cells carcinomas in vivo. Cancer Res., 2006, 66, 8026-8036 (Pubitemid 44299167)
9. Pahler, J.C.; Tazzyman, S.; Erez, N.; Chen, Y.Y.; Murdoch, C.; Nozawa, H., Lewis, C.E.; Hanahan, D. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia, 2008, 10, 329-340
10. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357, 539-545 (Pubitemid 32173595)
11. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol., 2002, 23, 549-555 (Pubitemid 35223554)
12. Naldini, A.; Carraro, F. Role of inflammatory mediators in angiogenesis. Curr. Drug Targets Inflamm. Allergy, 2005, 4, 3-8 (Pubitemid 40584847)
13. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T.H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell. Biol., 2000, 2, 737-744
14. Leek, R.D.; Lewis, C.E.; Whitehouse, R.; Greenall, M.; Clarke, J.; Harris, A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res., 1996, 56, 4625-4629 (Pubitemid 26338061)
15. Makitie, T.; Summanen, P.; Takkanen, A.; Kivela, T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophtalmol. Vis. Sci., 2001, 42, 1414-1421 (Pubitemid 32520728)
16. Nishie, A.; Ono, M.; Shono, T.; Fukushi, J.; Otsubo, M.; Onoue, H.; Ito, Y.; Inamura, T.; Ikezaki, K.; Fukui, M.; Iwaki, T.; Kuwano, M. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res., 1999, 5, 1107-1113 (Pubitemid 29233226)
17. Koide, N.; Nishio, A.; Sato, T.; Sugiyama, A.; Miyagawa, S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am. J. Gastroenterol., 2004, 99, 1667-1674 (Pubitemid 39237489)
18. Hanada, T.; Nakagawa, M.; Emoto, A.; Nomura, T.; Nasu, N.; Nomura, Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int. J. Urol., 2000, 7, 263-269 (Pubitemid 30440592)
19. Lissbrant, I.F.; Stattin, P.; Wikstrom, P.; Damber, J.E.; Egevad, L.; Bergh, A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int. J. Oncol., 2000, 17, 445-451
20. Qian, B.Z.; Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. Cell, 2010, 141, 39-51
21. Gazzaniga, S.; Bravo, A.I.; Guglielminotti, A.; van Rooijen, N.; Maschi, F.; Vecchi, A.; Mantovani, A.; Mordoh, J.; Wainstok, R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol., 2007, 127, 2031-2041 (Pubitemid 47075380)
22. Noonan, D.M.; De Lerma Barbaro, A.; Vannini, N.; Mortara, L.; Albini, A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev., 2008, 27, 31-40
23. Sica, A.; Larghi, P.; Mancino, A.; Rubino, L.; Porta, C.; Totaro, M.G.; Rimoldi, M.; Biswas, S.K.; Allavena, P.; Mantovani, A. Macrophage polarization in tumor progression. Semin. Cancer Biol., 2008, 18, 349-355
24. Joyce, J.A.; Pollard, J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer, 2009, 9, 239-252.
25. Sica, A.; Porta, C.; Riboldi, E.; Locati, M. Convergent pathways of macrophage polarization: the role of B cells. Eur. J. Immunol., 2010, 40, 2131-2133
26. Sica, A.; Porta, C.; Morlacchi, S.; Banfi, S.; Strauss, L.; Rimoldi, M.; Totaro, M.G.; Riboldi, E. Origin and functions of tumor-associated myeloid cells (TAMCs). Cancer Microenvironment, 2011 (in press)
27. Venneri, M.A.; De Palma, M.; Ponzoni, M.; Pucci, F.; Scielzo, C.; Zonari, E.; Mazzieri, R.; Doglioni, C.; Naldini, L. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood, 2007, 109, 5276-5285 (Pubitemid 46890548)
28. Colombo, M.P.; Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev., 2002, 13, 155-168 (Pubitemid 34229390)
29. Angiolillo, A.L.; Sgadari, C.; Taub, D.D.; Liao, F.; Farber, J.M.; Maheshwari, S.; Kleinman, H.K. Reaman, G.H.; Tosato, G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 1995, 182, 155-162
30. Romagnani, P.; Annunziato, F.; Lasagni, L.; Lazzeri, E.; Beltrame, C.; Francalanci, M.; Uguccioni, M.; Galli, G.; Cosmi, L.; Maurenzig, L.; Baggiolini, M.; Maggi, E.; Romagnani, S.; Serio, M. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest., 2001, 107, 53-63 (Pubitemid 32047414)
31. Dias, S.; Boyd, R.; Balkwill, F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int. J. Cancer, 1998, 78, 361-365 (Pubitemid 28445375)
32. Erez, N.; Truitt, M.; Olson, P.; Arron, S.T.; Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell, 2010, 17, 135-147
33. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y.J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol., 2000, 18, 767-811 (Pubitemid 30365397)
34. Mimura. K.; Kono, K.; Takahashi, A.; Kawaguchi, Y.; Fujii, H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol. Immunother., 2007, 56, 761-770 (Pubitemid 46723581)
35. Bourbié-Vaudanie, S.; Blanchard, N.; Hivroz, C.; Romeo, P.H. Dendritic cells can turn CD4+ T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer. J. Immunol., 2006, 177, 1460-1469 (Pubitemid 44092479)
36. Riboldi, E.; Musso, T.; Moroni, E.; Urbinati, C.; Bernasconi, S.; Rusnati, M.; Adorini, L.; Presta, M.; Sozzani, S. Proangiogenic properties of alternatively activated dendritic cells. J. Immunol., 2005, 175, 2788-2792 (Pubitemid 41170494)
37. Gottfried, E.; Kreutz, M.; Haffner, S.; Holler, E.; Iacobelli, M.; Andreesen, R.; Eissner, G. Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis. Scand. J. Immunol., 2007, 65, 329-335 (Pubitemid 46481100)
38. Ribatti, D.; Crivellato, E. Mast cells, angiogenesis and tumor growth. Biochim. Biophys. Acta, 2012, 1822, 2-8.
39. Huang, B.; Lei, Z.; Zhang, G.M., Li, D.; Song, C.; Li, B.; Liu, Y.; Yuan, Y.; Unkeless, J.; Xiong, H.; Feng, Z.H. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood, 2008, 112, 1269-1279
40. Coussens, L.M.; Raymond, W.W.; Bergers, G.; Laig-Webster, M.; Behrendstent, O.; Werb, Z.; Caughey, G.H.; Hanahan, D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev., 1999, 13, 1382-1397. (Pubitemid 29270244)
41. Hartveit F. Mast cells and metachromasia in human breast cancer: their occurrence, significance and consequence: a preliminary report. J. Pathol., 1981, 134, 7-11 (Pubitemid 11104666)
42. Lachter, J.; Stein, M.; Lichting, C.; Eidelman, S.; Munichor, M. Mast cells in colorectal neoplasias and premalignant disorders. Dis. Colon Rectum, 1995, 38, 290-293
43. Graham, R.; Graham, J. Mast cells and cancer of the cervix. Surg. Gynecol. Obstet., 1966, 123, 3-9
44. Bowrey, P.F.; King, J.; Magarey, C.; Schwartz, P.; Marr, P.; Bolton, E.; Morris, D.L. Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? Br. J. Cancer, 2000, 82, 167-170 (Pubitemid 30008977)
45. Benitez-Bribiesca, L.; Wong, A.; Utrera, D.; Castellanos, E. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J. Histochem. Cytochem., 2001, 49, 1061-1062 (Pubitemid 32675015)
46. Elpek, G.O.; Gelen, T.; Aksoy, N.H.; Erdogan, A.; Dertsiz, L.; Demircan, A.; Keleş, N. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J. Clin. Pathol., 2001, 54, 940-944 (Pubitemid 34032889)
47. Ribatti, D.; Vacca, A.; Ria, R.; Marzullo, A.; Nico, B.; Filotico, R.; Roncali, L.; Dammacco, F. Neovascularization, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur. J. Cancer, 2003, 39, 666-674 (Pubitemid 36287380)
48. Ribatti, D.; Ennas, M.G.; Vacca, A.; Ferreli, F.; Nico, B.; Orru, S.; Sirigu, P. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest., 2003, 33, 420-425 (Pubitemid 36583711)
49. Ribatti, D.; Finato, N.; Crivellato, E.; Marzullo, A.; Mangieri, D.; Nico, B.; Vacca, A.; Beltrami, C.A. Neovascularization and mast cells with tryptase activity increase simultaneously with pathological progression in human endometrial cancer. Am. J. Obstet. Gynecol., 2005, 193, 1961-1965 (Pubitemid 41737619)
50. Ribatti, D.; Nico, B.; Vacca, A.; Marzullo, A.; Calvi, N.; Roncali, L.; Dammacco, F. Do mast cells help to induce angiogenesis in B-cell non- Hodgkin's lymphomas? Br. J. Cancer, 1998, 77, 1900-1906 (Pubitemid 28254631)
51. Ribatti, D.; Vacca, A.; Nico, B.; Quondamatteo, F.; Ria, R.; Minischetti, M.; Marzullo, A.; Herken, R.; Roncali, L.; Dammacco, F. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br. J. Cancer, 1999, 79, 451-455 (Pubitemid 29046218)
52. Ribatti, D.; Vacca, A.; Marzullo, A.; Nico, B.; Ria, R.; Roncali, L.; Dammacco, F. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non- Hodgkin's lymphomas. Int. J. Cancer, 2000, 85, 171-175 (Pubitemid 30023063)
53. Ribatti, D.; Polimero, G.; Vacca, A.; Marzullo, A.; Crivellato, E.; Nico, B.; Lucarelli, G.; Dammacco, F. Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. Leukemia, 2002, 16, 1680-1684
54. Ribatti, D.; Molica, S.; Vacca, A.; Nico, B.; Crivellato, E.; Roccaro, A.M.; Dammacco, F. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia, 2003, 17, 1428-1430 (Pubitemid 36857360)
55. Fukushima, N.; Satoh, T.; Sano, M.; Tokunaga, O. Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma. Leuk. Lymphoma, 2001, 42, 709-720 (Pubitemid 32782779)
56. Molica, S.; Vacca, A.; Crivellato, E.; Cuneo, A.; Ribatti, D. Tryptase-positive mast cells predict clinical outcome of patients with B-cell chronic lymphocytioc leukemia. Eur. J. Haematol., 2003, 71, 137-139 (Pubitemid 36951650)
57. Sawatsubashi, M.; Yamada, T.; Fukushima, N.; Mizokami, H.; Tokunaga, O.; Shin, T. Association of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinoma. Virchows Arch. B Cell Pathol. Mol. Pathol., 2000, 436, 243-248
58. Imada, A.; Shijubo, N.; Koijma, H.; Abe, S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur. Resp. J., 2000, 15, 1087-1093
59. Takanami, I.; Takeuchi, K.; Naruke, M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer, 2000, 88, 2686-2692 (Pubitemid 30417928)
60. Tomita, M.; Matsuzaki, Y.; Onitsuka, T. Effect of mast cells on tumor angiogenesis in lung cancer. Ann. Thorac. Surg., 2000, 69, 1686-1689
61. Tóth-Jakatics, R.; Jimi, S.; Takebayashi, S.; Kawamoto, N. Cutaneous malignant melanoma: correlation between neovascularization and peritumoral accumulation of mast cells overexpressing vascular endothelial growth factor. Human Pathol., 2000, 31, 955-960
62. Gay, L.J.; Felding-Habermann, B. Contribution of platelets to tumor metastasis. Nat. Rev. Cancer, 2011, 11, 123-134
63. Klement, G.L.; Yip, T.T.; Cassiola, F.; Kikuchi, L.; Cervi, D.; Podustu, V.; Italiano, J.E.; Wheatley, E.; Abou-Slaybi, A.; Bender, E.; Almog, N.; Kieran, M.W.; Folkman, J. Platelets actively sequester angiogenesis regulators. Blood, 2009, 113, 2835-2842
64. Aurora, A.B.; Baluk, P.; Zhang, D., Sidhu, S.S.; Dolganov, G.M.; Basbaum, C.; McDonald, D.M.; Killeen, N. Immune complex-dependent remodeling of the airway vasculature in response to a chronic bacterial infection. J. Immunol., 2005, 175, 6319-6326 (Pubitemid 41598871)
65. Strasly, M.; Cavallo, F.; Guena, M., Mitola, S.; Colombo, M.P.; Forni, G.; Bussolino, F. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol., 2001, 166, 3890-3896
66. Trinchieri, G. Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today, 1993, 14, 335-338 (Pubitemid 23198164)
67. Yao, L.; Sgadari, C.; Furuke, K.; Bloom, E.T.; Teruya-Feldstein, J.; Tosato, G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood, 1999, 93, 1612-1621 (Pubitemid 29102489)
68. Cavallo, F.; Quaglino, E.; Cifaldi, L.; Di Carlo, E.; André, A.; Bernabei, P.; Musiani, P.; Forni, G.; Calogero, R.A. Interleukin 12-activated lymphocytes influence tumor genetic programs. Cancer Res., 2001, 61, 3518-3523 (Pubitemid 32700278)
69. Mantovani, A. B cells and macrophages in cancer: yin and yang. Nat. Med., 2011, 17, 285-286
70. DeNardo, D.G.; Anderu, P.; Coussens, L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev., 2010, 29, 309-316
71. DeNardo, DG.; Barreto, J.B.; Andreu, P.; Vasquez, L.; Tawfik, D.; Kolhatkar, N.; Coussens, L.M. CD4(+) cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 2009, 16, 91-102
72. Tsujii, M.; Kawano, S.; DuBois, R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A, 1997, 94, 3336-3340
73. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 1998, 93, 705-716 (Pubitemid 28257578)
74. Takahashi, Y.; Kawahara, F.; Noguchi, M.; Miwa, K.; Sato, H.; Seiki, M.; Inoue, H.; Tanabe, T., Yoshimoto, T. Activation of matrix metalloproteinase- 2 in human breast cancer cells overexpressing cyclooxygenase-1 or-2. FEBS Lett., 1999, 460, 145-148 (Pubitemid 29479260)
75. Macarthur, M.; Hold, G.L.; El-Omar, E.M. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286, G515-520 (Pubitemid 38374969)
76. Boccaccio, C.; Sabatino, G.; Medico, E.; Girolami, F.; Follenzi, A.; Reato, G.; Sottile, A.; Naldini, L.; Comoglio, P.M. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature, 2005, 434, 396-400 (Pubitemid 40469184)
77. Liu, X.H.; Kirschenbaum, A.; Lu, M.; Yao, S.; Dosoretz, A.; Holland, J.F.; Holland, J.F., Levine, A.C. Prostaglandin E2 induces hypoxia-inducible factor -1 alpha stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem., 2002, 277, 50081-50086 (Pubitemid 36014461)
78. Taketo, M.M. Cycloxygenase-2 inhibitor in tumorigenesis (Part II). J. Natl. Cancer Inst., 1998, 90, 1609-1620
79. Subbaramaiah, K.; Zakim, D.; Weksler, B.B.; Dannenberg, A.J. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med., 1997, 216, 201-210
80. Grinwick, K.D.; Plescia, O.J. Tumor-mediated immunosuppression: prevention by inhibitors of prostaglandin syntesis. Prostaglandins, 1977, 14, 1775-1782
81. Luca, M.; Huang, S.; Gershenwald, J.E.; Singh, R.K.; Reich, R.; Bar-Eli, M. Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol., 1997, 151, 1105-1113 (Pubitemid 27424320)
82. Hong, S.H.; Ondrey, F.G.; Avis, I.M.; Chen, Z.; Loukinova, E.; Cavanaugh, P.F. Jr.; Van Waes, C.; Mulshine, J.L. Cycloxygenase regulates human oropharingeal carcinomas via the pro-inflammatory cytokine IL-6: a general role for inflammation ? FASEB J., 2000, 14, 1499-1507 (Pubitemid 30636555)
83. Choi, H.; Milas, L. Enhancing radiotherapy with cycloxygenase-2 enzyme inhibitors: a rational advance ? J. Natl. Cancer Inst., 2003, 95, 1440-1452 (Pubitemid 37279329)
84. Dimopoulos, M.; Spencer, A.; Attal, M.; Prince, H.M.; Harousseau, J.L.; Dmosynska, A.; San Miguel, J.; Hellmann, A.; Facon, T.; Foà, R.; Corso, A.; Masliak, Z.; Olesnyckyi, M.; Yu, Z.; Patin, J.; Zeldis, J.B.; Knight, R.D. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med., 2007, 357, 2123-3232
85. Barlett, J.B.; Dredge, K.; Dalgleish, A.G. The evolution of thalidomide and its ImiD derivatives as anticancer agents. Nat. Rev. Cancer, 2004, 4, 314-322 (Pubitemid 38525287)
86. De Luisi, A.; Ferrucci, A.; Coluccia, A.M.; Ria, R.; Moschetta, M.; de Luca, E.; Pieroni, L.; Maffia, M.; Urbani, A.; Di Pietro, G.; Guarini, A.; Ranieri, G.; Ditonno, P.; Berardi, S.; Caivano, A.; Basile, A.; Cascavilla, N.; Capalbo, S.; Quarta, G.; Dammacco, F.; Ribatti, D.; Vacca, A. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin. Cancer Res. 2011, 17, 1935-1946.
87. Brown, J.R.; DuBois, R.N. COX-2: a molecular target for colorectal prevention. J. Clin. Oncol., 2005, 23, 2840-2845
88. Thun, M.J.; Namboodin, M.M. Aspririn use and reduced risk of fatal colon cancer. N. Engl. J. Med., 1991, 325, 1593-1596
89. Schreinemachers, D.M.; Everson, R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemilogy, 1994, 5, 138-146 (Pubitemid 24073387)
90. Funkhouser, E.M.; Sharp, G.B. Aspirin and reduced risk of esophageal carcinoma. Cancer, 1995, 76, 1116-1119
91. Mann, J.R.; Backlund, M.G.; Du Bois, R.N. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol., 2005, 2, 202-210 (Pubitemid 40812470)
92. Ulrich, C.M.; Bigler, J.; Potter, J.D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer., 2006, 6, 130-140 (Pubitemid 43361545)
93. Harris, R.E.; Beebe-Donk, J.; Alshafic, G.A. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. B.M.C. Cancer, 2006, 6, 27
94. Castelao, J.E.; Yuan, J.M.; Gago-Dominguez, M.; Yu, M.C.; Ross, R.K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Cancer, 2000, 82, 1364-1369 (Pubitemid 30145360)
95. Lejeune, F.J.; Monnier, Y.; Ruegg, C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res., 2006, 16, 263-265 (Pubitemid 44085101)
96. Giraudo, M.; Inoue, M.; Hanahan, D. An amino-bisphosphonate targets MMP-9 expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest., 2004, 114, 623-633 (Pubitemid 39578752)
97. Scavelli, C.; Di Pietro, G.; Cirulli, T.; Coluccia, M.; Boccarelli, A.; Giannini, T.; Mangialardi, G.; Bertieri, R.; Coluccia, A.M.; Ribatti, D.; Dammacco, F.; Vacca, A. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol. Cancer Ther., 2007, 6, 3256-3262
98. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grünwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; Urbanowitz, G.; Berg, W.J.; Kay, A.; Lebwohl, D.; Ravaud, A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 2008, 372, 449-456
99. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C.J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K.W.; Geissler, E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 2002, 8, 128-135 (Pubitemid 34155123)
100. Marimpietri, D.; Nico, B.; Vacca, A.; Mangieri, D.; Catarsi, P.; Ponzoni, M.; Ribatti, D. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene, 2005, 24, 6785-6795 (Pubitemid 41487037)
101. Marimpietri, D.; Brignole, C.; Nico, B.; Pastorino, F.; Pezzolo, A.; Piccardi, F.; Cilli, M.; Di Paolo, D.; Pagnan, G.; Longo, L.; Perri, P.; Ribatti, D.; Ponzoni, M. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin. Cancer Res., 2007, 13, 3977-3988 (Pubitemid 47037606)
102. Phung, T.L.; Eyiah-Mensah, G.; O'Donnell, R.K.; Bieniek, R.; Shechter, S.; Walsh, K.; Kuperwasser, C.; Benjamin, L.E. Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res., 2007, 67, 5070-5075 (Pubitemid 46997240)
103. Xue, Q.; Nagy, J.A.; Manseau, E.J.; Phung, T.L.; Dvorak, H.F.; Benjamin, L.E. Rapamycin inhibition of the Akt/mTor pathway blocks select stages of VEGF-A 164 driven angiogenesis, in part by blocking S6kinase. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 1172-1178
104. Aggarwall, B.B. Signaling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol., 2003, 3, 745-756
105. Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol., 2002, 2, 364-371 (Pubitemid 37328759)
106. Luttun, A.; Brusselmans, K.; Fukao, H.; Tjwa, M.; Ueshima, S.; Herbert, J.M.; Matsuo, O.; Collen, D.; Carmeliet, P.; Moons, L. Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem. Biophys. Res. Commun., 2002, 295, 428-434 (Pubitemid 34785852)
107. Lakings, D.B. Atiprimod AnorMED. Idrugs, 2003, 3, 329-335
108. Amit-Vazina, M.; Shishodia, S.; Harris, D.; Van, Q.; Wang, M.; Weber, D.; Alexanian, R.; Talpaz, M.; Aggarwal, B.B.; Estrov, Z. Atiprimod blocks STAt3 phosphorylation and induces apoptosis in multiple myeloma cells. Br. J. Cancer, 2005, 93, 70-80
109. Erba, F.; Fiorucci, L.; Pascarella, S.; Mnegatti, E.; Ascenzi, P.; Ascoli, F. Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug. Biochem. Pharmacol., 2001, 61, 271-276
110. Mori, S.; Itoh, Y.; Shinohata, R.; Senedo, T.; Oishi, R.; Nishibori, M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J. Pharmacol. Sci., 2003, 92, 420-423
111. Uchima, Y.; Sawada, T; Hirikawa, K. Action of antiproteases on pancreatic cancer cells. J. Pancreas, 2007, 8 (4 Suppl), 479-487
112. Ribatti, D.; Nico, B.; Crivellato, E.; Roccaro, A.M.; Vacca, A.M. The history of the angiogenic switch concept. Leukemia, 2007, 21, 44-52
113. Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307, 58-62 (Pubitemid 40093472)
114. Goel, S.; Duda, D.G.; Xu, L.; Munn, L.L.; Boucher, Y.; Fukumura, D.; Jain, R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev., 2011, 91, 1071-1021
115. Rolny, C.; Mazzone, M.; Tugues, S.; Laoui, D.; Johansson, I.; Coulon, C.; Squadrito, M.L.; Segura, I.; Li, X.; Knevels, E., Costa, S.; Vinckier, S.; Dresselaer, T.; Akerud, P.; De Mol, M.; Solomaki, H.; Phillipson, M.; Wyns, S.; Larsson, E.; Buysschaert, I.; Botling, J.; Himmelreich, U.; Van Ginderachter, J.A.; DePalma, M.; Dewerchin M.; Claesson-Welsh, L.; Carmeliet, P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell, 2011, 19, 31-44